Ultra-rapid 32-minute CGRP blood test for migraine diagnosis using mimotope-based immunoassay | Research

The takeaway

A one-step CGRP immunoassay using mimotope peptides achieved 32-minute analysis time with LOD of 8.8-9.4 pg/mL, successfully distinguishing migraine patients (n=57) from healthy controls (n=18) with results consistent with conventional assays.

32-minute migraine blood test
Mimotope-based immunoassay measures CGRP in 32 minutes—fast enough to prevent degradation—successfully distinguishing migraine patients from healthy controls

What the researchers found

Analysis time: 32 minutes. LOD: 8.8 pg/mL (fremanezumab mimotope F1), 9.4 pg/mL (galcanezumab mimotope G7). LOQ: 125.9 and 84.7 pg/mL. Successfully distinguished 57 migraine patients from 18 controls. Consistent with conventional CGRP assay.

Why it matters

CGRP measurement has been impractical clinically because the peptide degrades too quickly. A 32-minute test makes CGRP measurement feasible for point-of-care migraine diagnosis and treatment monitoring.

How the study worked

Mimotope peptide synthesis from Fv-antibody library (4 clones × 2 mAbs). 15-residue peptides. KD estimation. Docking simulations. One-step immunoassay development. Clinical validation (57 migraine + 18 control).

What this study cannot tell us

Small clinical sample (57+18). Single-center. LOQ values may limit quantification at low concentrations. Needs multi-center validation. Pre-analytical handling still critical.

How to read the evidence

Diagnostic validation with 75 clinical samples. Good proof of concept needing larger validation.

When this study was published

Published in 2025.

The bigger picture

This could transform migraine from a clinical diagnosis (based on symptoms) to a biomarker-confirmed diagnosis, enabling objective monitoring of anti-CGRP therapy effectiveness.

Questions still open

Could this test be adapted for point-of-care use?
Would monitoring CGRP guide anti-CGRP therapy dose adjustments?
Can the test distinguish migraine subtypes?

Common questions

Is there a blood test for migraines?

This study developed one. It measures CGRP—a neuropeptide elevated in migraine patients—in just 32 minutes using specialized mimotope peptides. In testing with 57 migraine patients and 18 healthy people, it successfully identified who had migraines, matching conventional test results.

Why does speed matter for this test?

CGRP breaks down rapidly in blood samples after collection. Standard tests take too long, so the CGRP degrades before it can be measured. This 32-minute test is fast enough to measure CGRP before it breaks down, making it practically usable in clinical settings.

Read the original research

One-step ultra-rapid immunoassay of calcitonin gene-related peptide for migraine diagnosis.

Biosensors & bioelectronics, 270, 116980

View on PubMed ↗Publisher’s paper ↗

Citation

Sung, Jeong Soo; Jung, Jaeyong; Kwon, Soonil; Bae, Hyung Eun; Kang, Min-Jung; Jose, Joachim; Lee, Misu; Cho, Soomi; Chu, Min Kyung; Pyun, Jae-Chul. (2025). One-step ultra-rapid immunoassay of calcitonin gene-related peptide for migraine diagnosis.. Biosensors & bioelectronics, 270, 116980. https://doi.org/10.1016/j.bios.2024.116980